HC Wainwright Issues Negative Forecast for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Eton Pharmaceuticals in a report released on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.09 per share for the quarter, down from their prior forecast of $0.12. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum increased their target price on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Trading Down 4.2 %

Shares of ETON stock opened at $10.02 on Friday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $11.11. The stock has a market cap of $258.92 million, a price-to-earnings ratio of -45.55 and a beta of 1.25. The stock has a 50-day moving average of $7.40 and a 200-day moving average of $4.98.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, major shareholder Opaleye Management Inc. acquired 16,852 shares of Eton Pharmaceuticals stock in a transaction dated Friday, October 4th. The stock was bought at an average price of $6.77 per share, with a total value of $114,088.04. Following the transaction, the insider now directly owns 2,720,000 shares in the company, valued at $18,414,400. This represents a 0.62 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have bought 85,600 shares of company stock valued at $462,674. 14.89% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eton Pharmaceuticals in the third quarter valued at $54,000. Jane Street Group LLC acquired a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at about $90,000. Renaissance Technologies LLC increased its position in Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in Eton Pharmaceuticals during the 2nd quarter worth approximately $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after acquiring an additional 30,167 shares in the last quarter. 27.86% of the stock is owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.